Nakai Takako, Okuyama Chio, Kubota Takao, Yamada Kei, Ushijima Yo, Taniike Keiko, Suzuki Takako, Nishimura Tsunehiko
Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1253-8. doi: 10.1007/s00259-005-1842-8. Epub 2005 Aug 20.
The purpose of this study was to investigate the pitfalls of using 2-[18F]-fluoro-2-deoxy-D: -glucose positron emission tomography (FDG-PET) for the evaluation of osteoblastic bone metastases in patients with breast cancer by comparing it with (99m)Tc-hydroxymethylene diphosphonate bone scintigraphy.
Among the 89 breast cancer patients (mean age 59+/-15 years) who had undergone both FDG-PET and bone scintigraphy within 1 month between September 2003 and December 2004, 55 with bone metastases were studied. The bone metastases were visually classified by multi-slice CT into four types according to their degree of osteosclerosis and osteolysis-osteoblastic, osteolytic, mixed and invisible-and compared in terms of tracer uptake on FDG-PET or bone scintigraphy and SUV(mean) on FDG-PET. Differences in the rate of detection on bone scintigraphy and FDG-PET were analysed for significance by the McNemar test.
The sensitivity, specificity and accuracy of bone scintigraphy were 78.2%, 82.4% and 79.8% respectively, and those of FDG-PET were 80.0%, 88.2% and 83.1%, respectively, revealing no significant differences. According to the CT image type, the visualisation rate of bone scintigraphy/FDG-PET was 100%/55.6% for the blastic type, 70.0%/100.0% for the lytic type, 84.2%/94.7% for the mixed type and 25.0%/87.5% for the invisible type. The visualisation rates of bone scintigraphy for the blastic type and FDG-PET for the invisible type were significantly higher. The SUV(mean) of the blastic, lytic, mixed and invisible types were 1.72+/-0.28, 4.14+/-2.20, 2.97+/-1.98 and 2.25+/-0.80, respectively, showing that the SUV(mean) tended to be higher for the lytic type than for the blastic type.
FDG-PET showed a low visualisation rate in respect of osteoblastic bone metastases. Although FDG-PET is useful for detection of bone metastases from breast cancer, it is apparent that it suffers from some limitations in depicting metastases of the osteoblastic type.
本研究旨在通过将2-[18F]-氟-2-脱氧-D-葡萄糖正电子发射断层扫描(FDG-PET)与(99m)Tc-亚甲基二膦酸盐骨闪烁显像进行比较,探讨其在评估乳腺癌患者成骨性骨转移中的缺陷。
在2003年9月至2004年12月期间1个月内同时接受FDG-PET和骨闪烁显像的89例乳腺癌患者(平均年龄59±15岁)中,对55例有骨转移的患者进行研究。根据多层CT将骨转移按骨硬化和骨溶解程度分为四种类型——成骨型、溶骨型、混合型和隐匿型——并比较FDG-PET或骨闪烁显像上的示踪剂摄取情况以及FDG-PET上的SUV(均值)。通过McNemar检验分析骨闪烁显像和FDG-PET检测率的差异是否具有显著性。
骨闪烁显像的敏感性、特异性和准确性分别为78.2%、82.4%和79.8%,FDG-PET的敏感性、特异性和准确性分别为80.0%、88.2%和83.1%,差异无显著性。根据CT图像类型,骨闪烁显像/FDG-PET的可视化率在成骨型中为100%/55.6%,溶骨型中为70.0%/100.0%,混合型中为84.2%/94.7%以及隐匿型中为25.0%/87.5%。成骨型的骨闪烁显像可视化率和隐匿型的FDG-PET可视化率显著更高。成骨型、溶骨型、混合型和隐匿型的SUV(均值)分别为1.72±0.28、4.14±2.20、2.97±1.98和2.25±0.80,表明溶骨型的SUV(均值)往往高于成骨型。
FDG-PET对成骨性骨转移的可视化率较低。虽然FDG-PET对检测乳腺癌骨转移有用,但显然在描绘成骨型转移方面存在一些局限性。